Data from a 12-month follow-up post-hoc analysis of the e-HEALING registry demonstrate that the Genous stent (OrbusNeich) achieves good, comparable clinical and safety outcomes in patients discontinuing dual antiplatelet therapy at 30 days and at six months. According to the study, clinical outcomes in patients treated with Genous were not associated with the duration of dual antiplatelet therapy. The study has been published online in Catheterization and Cardiovascular Interventions.
For the analysis, patients were analysed according to continuation or discontinuation of dual antiplatelet therapy at 30-day and 6-month landmarks, with each landmark constituting a new baseline and the outcomes were assessed up to 12 months after stent placement. Target vessel failure, the study’s main outcome, was 6.5% in patients continuing dual antiplatelet therapy at 30 days versus 6.3% in patients who stopped at 30 days and 2.4% in patients continuing therapy at six months versus 2.9% in patients who stopped at six months. Notably, no significant differences in stent thrombosis were observed in patients continuing dual antiplatelet therapy compared to those who stopped at 30 days or at six months.
“Studies have shown that early discontinuation of dual antiplatelet therapy after the placement of a drug eluting stent is associated with higher rates of stent thrombosis,” said Peter Damman, Academic Medical Center in Amsterdam and first author of the publication. “Unfortunately, for patients who are expected to be non-compliant with their course of dual antiplatelet therapy or for those who are at a high risk for bleeding, this therapy is not desirable. These results reaffirm the safety and efficacy of the Genous stent when accompanied by only one month of dual antiplatelet therapy and support the use of Genous as an alternative to drug eluting stents in cases where dual antiplatelet therapy may need to be stopped early after stenting.”
The study evaluated patient outcomes from e-HEALING, a multicentre, worldwide prospective clinical registry conducted in 31 countries outside of the United States that included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention and Genous stent implantation. For the analysis, target vessel failure was defined as target vessel-related cardiac death or myocardial infarction and target vessel revascularisation.
